- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07928167
Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer Patients
A Randomized Phase 2 Trial of Lenvatinib Plus Pembrolizumab With or Without Stereotactic Radiation Therapy in Patients With Clear-cell Metastatic Renal Cell Carcinoma, Low Tumor Burden, and Stable Disease.
Metastatic clear-cell renal cell carcinoma (ccRCC) is sensitive to therapy with lenvatinib and pembrolizumab. The CLEAR trial demonstrated positive outcomes even in patients with a low tumor burden. In a subset of patients with metastatic ccRCC, the presence of a low tumor burden suggests that incorporating stereotactic body radiotherapy (SBRT) into systemic therapy could be a strategy to enhance the anti-tumor response, while maintaining an acceptable toxicity profile. This study evaluates the contribution of SBRT in a subgroup of patients who have achieved stable disease while receiving lenvatinib and pembrolizumab.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Metastatic clear cell renal cell carcinoma (mRCC) is sensitive to combination of lenvatinib and pembrolizumab. The CLEAR study showed positive results in patients with low tumor burden. However, around 20% of patients do not respond and have stable disease. In the VOLGA study, we demonstrated better outcomes in patients with irradiation of even a single lesion during targeted therapy. Thus, investigators hypothesize that stereotactic radiotherapy (SBRT) to multiple lesions in patients undergoing ongoing therapy with pembrolizumab and lenvatinib will increase the objective response rate, which may correlate with improved overall survival.
LASER is a randomized multicenter phase 2 study. Initially, all patients with histologically confirmed mRCC, the median sum of the diameters of target lesions ≥ 7 cm, ECOG 0-2, and the absence of prior systemic therapy for metastatic disease will receive a 12-week induction with lenvatinib and pembrolizumab, followed by radiological assessment according to RECIST 1.1 and allocation by outcome (response, stable disease, or disease progression). Patients with stable disease (SD) will be randomized in a 1:1 ratio into two groups: 1) lenvatinib + pembrolizumab + SBRT (N=27) or 2) lenvatinib + pembrolizumab alone (N=27). In the SBRT group, the choice of target for irradiation - up to 3 (three) lesions - is determined by a multidisciplinary team. The primary endpoint is the objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease (assessed every 12 weeks according to RECIST 1.1). The statistical hypothesis is based on an expected ORR of 15% in the control group versus 50% in the SBRT group. A two-sided α of 0.05 and a power of 80% require 27 patients in each group (54 randomized). The total enrollment will be 150 patients.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Ilya Tsimafeyeu
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
Studie Locaties
-
-
-
Kazan', Rusland, 420000
- Werving
- Republican Dispensary of Tatarstan
-
Contact:
- Milyausha Mukhitova
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Rusland, 115478
- Werving
- N.N. Blokhin National Medical Research Center of Oncology
-
Contact:
- Petr Bulychkin
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Moscow, Rusland, 125630
- Werving
- STOONCO clinic
-
Contact:
- Valentina Leonenko
- Telefoonnummer: +7 (915) 809-03-03
- E-mail: bucare@bucare.org
-
Orenburg, Rusland, 460000
- Werving
- Orenburg Regional Cancer Center
-
Contact:
- Makhabbat Murzalina
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Saint Petersburg, Rusland, 194291
- Werving
- SBHI Leningrad Regional Clinical Hospital
-
Contact:
- Andrey Lebedinets
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Tyumen, Rusland, 625000
- Werving
- Cancer Center "Medical City"
-
Contact:
- Vera Peryshkina
- Telefoonnummer: +74999054690
- E-mail: sten_to@mail.ru
-
Ufa, Rusland, 450000
- Werving
- Republican Clinical Oncology Dispensary
-
Contact:
- Alexander Sultanbaev
- Telefoonnummer: +7 (347) 216-3671
- E-mail: ufa.rkod@doctorrb.ru
-
Ulyanovsk, Rusland, 432000
- Werving
- "ErSpace" Radiation Therapy Center
-
Contact:
- Natalia Dengina
- Telefoonnummer: +78422737472
- E-mail: info@rspei.ru
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically confirmed clear-cell renal cell carcinoma.
- Presence of measurable lesions per RECIST 1.1.
- Sum of diameters of target lesions ≤ 7 cm.
- ECOG 0-2.
- No prior systemic therapy for metastatic disease.
Exclusion Criteria:
- Uncontrolled comorbidities that preclude the use of TKI/IO or SBRT.
- Prior SBRT to the lesions planned for irradiation, rendering re-irradiation unsafe.
- Active autoimmune diseases requiring systemic immunosuppressants.
- Symptomatic CNS metastases (patients with asymptomatic metastases may be included).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Lenvatinib + Pembrolizumab + SBRT
|
20 mg orally once daily. 200 mg intravenously every 3 weeks The dosage regimen is determined by a radiation oncologist and depends on the location of the lesion. |
|
Actieve vergelijker: Lenvatinib + Pembrolizumab
|
20 mg orally once daily. 200 mg intravenously every 3 weeks |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants with Response of unirradiated lesions according to RECIST v1.1
Tijdsspanne: Percentage of patients with response at week 12
|
Objective response rate (ORR) of unirradiated lesions after randomization among patients with stable disease |
Percentage of patients with response at week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Median progression-free survival
Tijdsspanne: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.
|
|
Median overall survival
Tijdsspanne: From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
From date of randomization until the date of death from any cause, whichever came first, assessed up to 60 months.
|
|
Median duration of response
Tijdsspanne: From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
From the first response to the date of disease progression or death for any reason, whichever came first, assessed up to 36 months.
|
|
Rate of local control of irradiated lesions
Tijdsspanne: Percentage of stable irradiated lesions at week 12
|
Percentage of stable irradiated lesions at week 12
|
|
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Tijdsspanne: Rate of treatment-related adverse events at week 24
|
Rate of treatment-related adverse events at week 24
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Ilya Tsimafeyeu et al. A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).. J Clin Oncol 44, TPS583-TPS583(2026). DOI:10.1200/JCO.2026.44.7_suppl.TPS583
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Pathologische processen
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Neoplastische processen
- Urologische neoplasmata
- Carcinoom
- Nierneoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Neoplasma metastase
- Carcinoom, niercel
- Onderzoekstechnieken
- Therapeutica
- Chirurgische procedures, operatief
- Radiotherapie
- Stereotaxische technieken
- Neurochirurgische procedures
- pembrolizumab
- Radiochirurgie
- Lenvatinib
Andere studie-ID-nummers
- LASER
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
In accordance with local legislation
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .